Stabilization of tooth movement by administration of reveromycin A to osteoprotegerin-deficient knockout mice

American Journal of Orthodontics and Dentofacial Orthopedics

Volumn 144, Issue 3, 2013, Pages 368-380

  Yabumoto, Takahiro ^a   Miyazawa, Ken ^a   Tabuchi, Masako ^a   Shoji, Satsuki ^a   Tanaka, Miyuki ^a   Kadota, Manami ^a   Yoshizako, Mamoru ^a   Kawatani, Makoto ^b   Osada, Hiroyuki ^b   Maeda, Hatsuhiko ^a   Goto, Shigemi ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; OSTEOPROTEGERIN; PYRAN DERIVATIVE; REVEROMYCIN A; SPIRO COMPOUND; TRANSCRIPTION FACTOR RUNX2;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BONE REMODELING; DENTAL PROCEDURE; DISEASE MODEL; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; MALE; MOUSE; PAGET BONE DISEASE; PERIODONTAL DISEASE; RECURRENT DISEASE;

ALVEOLAR BONE LOSS; ANIMALS; ANTIMITOTIC AGENTS; BONE REMODELING; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DENTAL STRESS ANALYSIS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, KNOCKOUT; OSTEITIS DEFORMANS; OSTEOPROTEGERIN; PYRANS; RECURRENCE; SPIRO COMPOUNDS; TOOTH MOVEMENT;

EID: 84886415497     PISSN: 08895406     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajodo.2013.04.016     Document Type: Article

References (57)

1. Yokoya K, Sasaki T, Shibasaki Y. Distributional changes of osteoclasts and pre-osteoclastic cells in periodontal tissues during experimental tooth movement as revealed by quantitative immunohistochemistry of H(1)-ATPase. J Dent Res 1997;76:580-7. (Pubitemid 127732638)
2. Sato Y, Sakai H, Kobayashi Y, Shibasaki Y, Sasaki T. Bisphosphonate administration alters subcellular localization of vacuolartype H1-ATPase and cathepsin K in osteoclasts during experimental movement of rat molars. Anat Rec 2000;260: 72-80.
3. Zahrowski JJ. Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis. Am J Orthod Dentofacial Orthop 2009;135:361-74.
4. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57. (Pubitemid 30649812)
5. Kong YY, Yashida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397: 315-23.
6. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24. (Pubitemid 29453612)
7. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-71. (Pubitemid 30118482)
8. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12. (Pubitemid 30026926)
9. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19. (Pubitemid 27199902)
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8. (Pubitemid 28213402)
11. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem Biophys Res Commun 1998; 247:610-5. (Pubitemid 28418439)
12. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;347:175-84. (Pubitemid 34764821)
13. Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002;11:2119-27. (Pubitemid 34994000)
14. Cundy T, Wheadon L, King A. Treatmant of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res 2004;19:703-11. (Pubitemid 41094379)
15. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(Supp 2):S66-80. (Pubitemid 29231759)
16. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17: 137-44.
17. Osada H, Koshino H, Isono K, Takahashi H, Kawanishi G, Reveromycin A. a new antibiotic which inhibits the mitogenic activity of epidermal growth factor. J Antibiot 1991;44: 259-61.
18. Woo JT, Kawatani M, Kato M, Shinki T, Yonezawa T, Kanoh N, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci USA 2006;103:4729-34.
19. Muguruma H, Yano S, Kakiuchi S, Uehara H, Kawatani M, Osada H, et al. Reveromycin A inhibits osteolytic bone metastasis of smallcell lung cancer cells, SBC-5, through an antiosteoclastic activity. Clin Cancer Res 2005;11:8822-8. (Pubitemid 43005934)
20. Watanabe T, Okafuji N, Nakano K, Shimizu T, Muraoka R, Kurihara S, et al. Periodontal tissue reaction to mechanical stress in mice. J Hard Tissue Biol 2007;16:71-4.
21. Watanabe T, Nakano N, Muraoka R, Shimizu T, Okafuji N, Kurihara S, et al. Role of Msx2 as a promoting factor for Runx2 at the periodontal tension sides elicited by mechanical stress. Eur J Med Res 2008;13:425-31.
22. Shoji S, Tabuchi M, Miyazawa K, Yabumoto T, Tanaka M, Kadota M, et al. Bisphosphonate inhibits bone turnover in OPG (-/-) mice via a depressive effect on both osteoclasts and osteoblasts. Calcif Tissue Int 2010;87:181-92.
23. Sprogar S, Vaupotic T, Cor A, Drevensek M, Drevensek G. The endothelin system mediates bone modeling in the late stage of orthodontic tooth movement in rats. Bone 2008;43:740-7.
24. Kimmel DB, Jee WSS. Measurements of area, perimeter, and distance: details of data collection in bone histomorphometry. In: Recker RR, editor. Bone histomorphometry: Techniques and interpretation. Boca Raton, Fla: CRC Press; 1983. p. 89-108.
25. Ralston SH. Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders. Best Pract Res Clin Rheumatol 2008;22:101-11. (Pubitemid 351325731)
26. Nakatsuka K, Nishizawa Y, Ralston SH. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 2003;18: 1381-5. (Pubitemid 41070792)
27. Golob DB, McAlister WH, Mills BG, Fedde KN, Reinus WR, Teitelbaum SL, et al. Juvenile Paget disease: life-long feature of a mildly affected young woman. J Bone Miner Res 1996;11: 132-42. (Pubitemid 26026753)
28. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003;144:5441-9. (Pubitemid 37476073)
29. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 2005;353:918-23. (Pubitemid 41247931)
30. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5:618-25. (Pubitemid 41614462)
31. Demir E, Bereket A, Ozkan B, Topçu M. Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J Pediatr Endocrinol Metab 2000; 13:217-21. (Pubitemid 30117220)
32. MacGowan JR, Pringle J, Morris VH, Stamp TC. Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. Skeletal Radiol 2000;29:279-82. (Pubitemid 30330734)
33. Brown JP, Hosking DJ, Ste-Marie L, Johnston CC Jr, Reginster J, Ryan WG, et al. Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study. Calcif Tissue Int 1999;64:93-9. (Pubitemid 29059373)
34. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and vivo. J Bone Miner Res 1995;10:1478-87.
35. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-9. (Pubitemid 16081453)
36. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100. (Pubitemid 29122075)
37. Lehmann HJ, Mouritzen U, Christgau S, Cloos PA, Christiansen C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 2002;61:530-3. (Pubitemid 34539098)
38. Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone 2003;32:268-74. (Pubitemid 36349530)
39. Kimura M, Miyazawa K, Tabuchi M, Maeda H, Kameyama Y, Goto S. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. Calcif Tissue Int 2008; 82:137-47.
40. Tabuchi M, Miyazawa K, Kimura M, Maeda H, Kawai T, Kameyama Y, et al. Enhancement of crude morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. Calcif Tissue Int 2005;77:239-49. (Pubitemid 41531504)
41. Antoniades K, Karakasis D, Kapetanos G, Lasaridis N, Tzarou V. Chronic idiopathic hyperphosphatasemia. Case report. Oral Surg Oral Med Oral Pathol 1993;76:200-4. (Pubitemid 23262579)
42. Whyte MP, Singhellakis PN, Petersen MB, Davies M, Totty WG, Mumm S. Juvenile Paget's disease: The second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966-969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels. J Bone Miner Res 2007;22:938-46. (Pubitemid 351339754)
43. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6. (Pubitemid 351439247)
44. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007;13:485-9. (Pubitemid 351206686)
45. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15. (Pubitemid 37152030)
46. Landis BN, Richter M, Dojcinovic I, Hugentobler M. Osteonecrosis of the jaw after treatment with bisphosphonates is irreversible, so the focus must be on prevention. BMJ 2006;333:982-3. (Pubitemid 44764343)
47. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
48. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93. (Pubitemid 40847755)
49. Ubukata M, Tanaka C, Osada H, Isono K. Respinomycin A1, a new anthracycline antibiotic. J Antibiot 1991;44:1274-6.
50. Cui Z, Hirata D, Tsuchiya E, Osada H, Miyakawa T. The multidrug resistance-associated protein (MRP) subfamily (Yrs1/Yor1) of saccharomyces cerevisiae is important for the tolerance to a broad range of organic anions. J Biol Chem 1996;271:14712-6. (Pubitemid 26194947)
51. Miyamoto Y, Machida K, Mizunuma M, Emoto Y, Sato N, Miyahara K, et al. Identification of saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific inhibitor reveromycin A. J Biol Chem 2002;277:28810-4.
52. Tanaka M, Miyazawa K, Tabuchi M, Yabumoto T, Kadota M, Yoshizako M, et al. Effect of reveromycin A on experimental tooth movement in OPG-/- mice. J Dent Res 2012;91:771-6.
53. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): A fourcase report. J Oral Pathol Med 2005;34:613-7. (Pubitemid 41512948)
54. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67:2-12.
55. Zahrowski JJ. Bisphosphonate treatment: An orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 2007;131:311-20.
56. Rinchuse DJ, Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: A report of 2 cases. Am J Orthod Dentofacial Orthop 2007; 131:321-6.
57. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-15. (Pubitemid 38388576)